PA
MYGN icon

Perceptive Advisors’s Myriad Genetics MYGN Stock Holding History

Perceptive Advisors’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-10,000
Closed -$210K – 140
2013
Q4 		$210K Buy
+10,000
New +$253K 0.03% 87

Other funds holding MYGN

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

Perceptive Advisors's MYGN Position: Q2 2016 in Review

Perceptive Advisors sold out of Myriad Genetics (MYGN) in Q2 2016, closing a stake of 3,333 shares — an estimated $125K sold.

Perceptive Advisors first reported a position in MYGN in Q2 2015 and held it in 4 quarters. The position peaked at $125K in Q1 2016. 252 funds tracked by Wall St. Rank hold MYGN as of Q2 2016.

  • Perceptive Advisors reported no remaining Myriad Genetics position as of Q2 2016 after selling out during the quarter.
  • Perceptive Advisors sold 3,333 Myriad Genetics shares in Q2 2016, an estimated $125K.
  • Perceptive Advisors first reported a position in Myriad Genetics in Q2 2015 and held it in 4 quarters.
  • Perceptive Advisors's Myriad Genetics position peaked at $125K in Q1 2016.
  • 252 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2016.

Based on Perceptive Advisors's 13F filing for Q2 2016, filed 11 Aug 2016.